Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.

Autor: Silk SE; Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Kalinga WF; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Salkeld J; Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Mtaka IM; Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Ahmed S; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Milando F; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Diouf A; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Bundi CK; Kenya Medical Research Institute (KEMRI) Centre for Geographic Medicine, KEMRI-Wellcome Trust Research Programme and Accredited Research Centre, Open University, Kilifi, Kenya., Balige N; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Hassan O; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Mkindi CG; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Rwezaula S; Muhimbili National Hospital, Dar es Salaam, Tanzania., Athumani T; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Mswata S; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Lilolime NS; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Simon B; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Msami H; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Mohamed M; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., David DM; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Mohammed L; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Nyaulingo G; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Mwalimu B; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Juma O; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Mwamlima TG; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Sasamalo IA; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Mkumbange RP; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Kamage JJ; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Barrett JR; Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., King LDW; Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Hou MM; Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Pulido D; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Oxford, UK., Carnrot C; Novavax AB, Uppsala, Sweden., Lawrie AM; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Oxford, UK., Cowan RE; Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Nugent FL; Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Roberts R; Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Cho JS; Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Long CA; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Nielsen CM; Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Miura K; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Draper SJ; Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Olotu AI; Interventions and Clinical Trials Department, Ifakara Health Institute, Bagamoyo, Tanzania., Minassian AM; Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. Electronic address: angela.minassian@bioch.ox.ac.uk.

Publikováno v: The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Oct; Vol. 24 (10), pp. 1105-1117. Date of Electronic Publication: 2024 Jun 13.

Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults.

Autor: Silk SE; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus, Oxford OX3 7LE, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK., Kalinga WF; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Mtaka IM; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Lilolime NS; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Mpina M; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Milando F; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Ahmed S; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Diouf A; Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA., Mkwepu F; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Simon B; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Athumani T; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Rashid M; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Mohammed L; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Lweno O; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Ali AM; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Nyaulingo G; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Mwalimu B; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Mswata S; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Mwamlima TG; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania., Barrett JR; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus, Oxford OX3 7LE, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK., Wang LT; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK., Themistocleous Y; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus, Oxford OX3 7LE, UK., King LDW; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus, Oxford OX3 7LE, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK., Hodgson SH; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus, Oxford OX3 7LE, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK., Payne RO; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus, Oxford OX3 7LE, UK., Nielsen CM; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus, Oxford OX3 7LE, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK., Lawrie AM; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus, Oxford OX3 7LE, UK., Nugent FL; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus, Oxford OX3 7LE, UK., Cho JS; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus, Oxford OX3 7LE, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK., Long CA; Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA., Miura K; Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA., Draper SJ; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus, Oxford OX3 7LE, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK., Minassian AM; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK; Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus, Oxford OX3 7LE, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford OX1 3QU, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: angela.minassian@bioch.ox.ac.uk., Olotu AI; Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania.

Publikováno v: Med (New York, N.Y.) [Med] 2023 Oct 13; Vol. 4 (10), pp. 668-686.e7. Date of Electronic Publication: 2023 Aug 11.